TICKERNERD
Menu
OMDAOMDAHealthcare · Health Information Services

OMDA Stock Forecast: Omada Health, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$24
+0.76% on the day

The 12 Wall Street analysts covering Omada Health, Inc. hold a median 12-month price target of $28 — +17.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
85 / 100
Median analyst target
$28
Analysts covering
12
Total return, dividends reinvested
1W
−0.6%
1M
+3.9%
YTD
+51.4%
1Y
+11.3%
From 52W high
−10.8%
From 52W low
+118.4%
$11
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OMDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Omada Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
85 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
92
Growth
88
Issuance
79
Quality
72
Accruals
68
Momentum
59
Size
41
Value
34
Volatility
19

Revisions (92): Analysts have, on balance, been raising their forecasts.

Volatility (19): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OMDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OMDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26OMDAHigh $35Median $28Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $22Median $28High $35

The green dot is the last close — the median target sits +17.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026CitizensMaintainsMarket Outperform$27 → $32
14 Aug 2026JP MorganMaintainsOverweight$26 → $30
12 Aug 2026BairdMaintainsNeutral$15 → $25
10 Aug 2026BTIGMaintainsBuy$30 → $35
3 Aug 2026BarclaysMaintainsOverweight$20 → $25
3 Aug 2026BarclaysMaintainsOverweight—
21 July 2026Canaccord GenuityMaintainsBuy—
21 July 2026Canaccord GenuityMaintainsBuy$24 → $28
20 July 2026CitizensMaintainsMarket Outperform—
20 July 2026CitizensMaintainsMarket Outperform$21 → $27
17 July 2026BTIGInitiatesBuy—
17 July 2026BTIGInitiatesBuy$30
22 June 2026Morgan StanleyReiteratesOverweight$30
22 June 2026Morgan StanleyReiteratesOverweight—
8 May 2026BarclaysMaintainsOverweight—
8 May 2026CitizensMaintainsMarket Outperform—
8 May 2026Evercore ISI GroupMaintainsOutperform—
8 May 2026NeedhamReiteratesBuy—
8 May 2026Wells FargoMaintainsEqual-Weight—
14 Apr 2026CitizensInitiatesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OMDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+33.5%
Analysts raising
2
Analysts cutting
0
Fundamentals

Omada Health, Inc. (OMDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
35.7×

Cheaper than 22% of US stocks

Price / sales
4.7×

Cheaper than 27% of US stocks

Price / book
6.0×

Cheaper than 18% of US stocks

EV / EBITDA
228.5×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
43.1%

Higher than 84% of US stocks

Earnings growth (YoY)
43.1%

Higher than 72% of US stocks

Gross margin
72.6%

Higher than 85% of US stocks

Operating margin
4.0%

Higher than 53% of US stocks

Net margin
1.4%

Higher than 50% of US stocks

Returns & dividend
Return on equity
1.8%

Higher than 47% of US stocks

Return on assets
−0.1%

Higher than 43% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OMDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
OMDAOmada Health, Inc.$1.5B
85
SDGRSchrödinger, Inc.$1.5B
53
CERTCertara, Inc.$1.3B
55
OMCLOmnicell, Inc.$1.6B
98
GDRXGoodRx Holdings, Inc.$1.2B
75
TDOCTeladoc Health, Inc.$1.1B
68
TALKTalkspace, Inc.$879.4M
—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Omada Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OMDA news & analysis

Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings

Seeking Alpha · 12 Aug 2026positive

Omada Health reported strong Q2 results with 43% revenue growth, margin expansion, and positive adjusted EBITDA, driven by product expansion in diabetes and hypertension and improved customer lifetime value through multi-program adoption.

Why it matters — The results indicate Omada's growth is increasingly translating into earnings, with channel partnerships and AI initiatives supporting scalable operations and better unit economics.

Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy

MarketBeat · 11 Aug 2026positive

At the Canaccord Genuity Growth Conference, Omada Health highlighted record second-quarter revenue and margin performance, and outlined plans to expand across cardiometabolic conditions, deepen channel partnerships, and leverage GLP-1-related demand to broaden customer relationships.

Why it matters — A record Q2 revenue and margin performance, combined with a clear strategy to capitalize on GLP-1 demand and expand partnerships, signals strong execution and growth momentum for Omada.

Omada Health, Inc. (OMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 8 Aug 2026neutral

Zacks Investment Research published a review of Omada Health, Inc.'s (OMDA) Q2 2026 earnings, comparing key metrics against Wall Street estimates and year-ago figures. The piece notes that revenue and EPS provide a sense of the company's performance for the quarter ended June 2026.

Why it matters — A OMDA watcher would care because the comparison of key metrics to analyst estimates and prior-year results offers insight into how the company's quarterly performance measured up to expectations.

Omada Health, Inc. (OMDA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Omada Health, Inc. held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management discussion.

Why it matters — OMDA watchers would care because the earnings call transcript provides direct insight into the company's quarterly performance and management's outlook.

Omada Health Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Omada Health reported record second-quarter results for 2026, driven by growth in cardiometabolic programs, expanded channel partnerships, and lower member-service costs. The company also announced that President Wei-Li Shao will succeed co-founder and CEO Sean Duffy as chief executive on Jan. 1, 2027.

Why it matters — The leadership transition and record financial results signal a strategic shift at a pivotal growth stage for Omada Health.

FAQ

Frequently asked questions about OMDA stock

What is the OMDA stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Omada Health, Inc. have a median 12-month price target of $28, with estimates ranging from $22 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OMDA stock a buy right now?

Of the 12 analysts covering Omada Health, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omada Health, Inc. 85 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OMDA?

As at 22 Aug 2026, Omada Health, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).

Will OMDA stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +17.2% from the last close, and Ticker Nerd's factor model ranks Omada Health, Inc. 85 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OMDA stock forecast for 2030?

No analyst covering Omada Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $35 over the next 12 months.

How has OMDA stock performed over the past year?

Omada Health, Inc. returned +11.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Omada Health, Inc. do?

Omada Health Inc. is a healthcare technology company specializing in virtual-first care programs focused on chronic disease prevention and management.

What is the latest news on OMDA?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings". Omada Health reported strong Q2 results with 43% revenue growth, margin expansion, and positive adjusted EBITDA, driven by product expansion in diabetes and hypertension and improved customer lifetime value through multi-program adoption.

Company

About Omada Health, Inc.

Omada Health Inc. is a healthcare technology company specializing in virtual-first care programs focused on chronic disease prevention and management. Founded in 2011 and headquartered in San Francisco, the company delivers digital solutions designed to support individuals in managing conditions such as diabetes, hypertension, and musculoskeletal disorders. Omada Health provides personalized care plans that combine human coaching, connected smart health devices, and interactive digital tools to guide members toward sustainable lifestyle changes. The company's services are tailored for employers, health plans, health systems, pharmacy benefit managers, and other organizations seeking to improve health outcomes and reduce long-term care costs. With a user-centric approach, Omada Health has served over a million members and collaborates with thousands of corporate partners across diverse sectors, including education, retail, and manufacturing. By leveraging data-driven insights and a multidisciplinary care team, Omada Health plays a pivotal role in the health information services sector, aiming to "bend the curve" of chronic disease through accessible, engaging, and effective virtual care solutions.

CEO Mr. Sean P. Duffy · 946 employees · United States · https://www.omadahealth.com